I 

118TH CONGRESS 

1ST SESSION H. R. 6749 

To require the Director of the National Institutes of Health to evaluate 

the results and status of completed and ongoing research related to 

menopause, perimenopause, or mid-life women’s health, to conduct and 

support additional such research, and for other purposes. 

IN THE HOUSE OF REPRESENTATIVES 

DECEMBER 13, 2023 

Ms. CLARKE of New York (for herself, Mrs. LESKO, Ms. BLUNT ROCHESTER, 

Ms. HOULAHAN, Mr. RYAN, Ms. WILD, Ms. LEE of California, Mrs. 

CAMMACK, Ms. VELA ́ZQUEZ, Mr. POSEY, Ms. SEWELL, Mr. GRIJALVA, 

Ms. TLAIB, Ms. WILLIAMS of Georgia, Mrs. RAMIREZ, Mr. TONKO, Ms. 

NORTON, Mr. NADLER, Ms. MOORE of Wisconsin, Mr. DAVIS of North 

Carolina, Ms. PORTER, Mr. GREEN of Texas, Ms. CROCKETT, Mr. 

ALLRED, Mrs. CHERFILUS-MCCORMICK, Ms. KELLY of Illinois, Mr. 

JACKSON of Illinois, Mr. LAWLER, Mrs. WATSON COLEMAN, Ms. 

BARRAGA ́N, Ms. CARAVEO, Mr. GARCI ́A of Illinois, Mr. TRONE, Mr. 

VARGAS, Mrs. BEATTY, Mrs. FLETCHER, Mr. FITZPATRICK, Ms. 

KUSTER, Ms. ADAMS, Ms. PINGREE, and Mr. TAKANO) introduced the 

following bill; which was referred to the Committee on Energy and Commerce 

A BILL 

To require the Director of the National Institutes of Health 

to evaluate the results and status of completed and ongoing research related to menopause, perimenopause, or 

mid-life women’s health, to conduct and support additional such research, and for other purposes. 

1 Be it enacted by the Senate and House of Representa2 tives of the United States of America in Congress assembled, 

2 

•HR 6749 IH

1 SECTION 1. SHORT TITLE. 

2 This Act may be cited as the ‘‘Menopause Research 

3 and Equity Act of 2023’’. 

4 SEC. 2. EVALUATION OF COMPLETED AND ONGOING RE5 SEARCH RELATED TO MENOPAUSE, 

6 PERIMENOPAUSE, OR MID-LIFE WOMEN’S 

7 HEALTH. 

8 (a) IN GENERAL.—The Director of the National In9 stitutes of Health shall— 

10 (1) conduct an evaluation of— 

11 (A) the results of research related to meno12 pause, perimenopause, or mid-life women’s 

13 health that is complete; 

14 (B) the status of such research that is on15 going; and 

16 (C) any gaps in knowledge and research 

17 on— 

18 (i) treatments for menopause-related 

19 symptoms; and 

20 (ii) the safety and effectiveness of 

21 treatments for menopause-related symp22 toms; and 

23 (2) as part of such evaluation, identify the total 

24 amount of funding allocated by the National Insti25 tutes of Health for the conduct or support of re26 search related to menopause, perimenopause, or 

3 

•HR 6749 IH

1 mid-life women’s health over the preceding 5 fiscal 

2 years. 

3 (b) REPORT; STRATEGIC PLAN.—Not later than 180 

4 days after the date of enactment of this Act, the Director 

5 of the National Institutes of Health shall submit to the 

6 Congress— 

7 (1) a plan to perform the evaluation under sub8 section (a); and 

9 (2) a plan to develop a strategy, based on such 

10 evaluation, that will— 

11 (A) be designed and implemented by the 

12 Director in cooperation with a multidisciplinary 

13 group of health professionals including gyne14 cologists, oncologists, endocrinologists, cardiolo15 gists, and neuroscientists; 

16 (B) include strategies to resolve the gaps 

17 in knowledge and research identified in the re18 port; and 

19 (C) identify topics in need of further re20 search relating to potential treatments for 

21 menopause-related symptoms. 

22 SEC. 3. ADDITIONAL RESEARCH RELATED TO MENOPAUSE, 

23 PERIMENOPAUSE, OR MID-LIFE WOMEN’S 

24 HEALTH. 

25 (a) ADDITIONAL RESEARCH.— 

4 

•HR 6749 IH

1 (1) IN GENERAL.—The Secretary of Health and 

2 Human Services, acting through the Director of the 

3 National Institutes of Health, shall conduct or sup4 port research related to menopause, perimenopause, 

5 or mid-life women’s health. 

6 (2) REQUIRED ELEMENTS.—The research re7 quired by paragraph (1) shall include— 

8 (A) research concerning causes, symptoms, 

9 and treatments for menopause, perimenopause, 

10 and other related mid-life women’s health 

11 issues; and 

12 (B) a multidisciplinary study of the effects 

13 of hormonal treatment for menopausal symp14 toms. 

15 SEC. 4. NO ADDITIONAL FUNDS AUTHORIZED TO BE APPRO16 PRIATED. 

17 No additional funds are authorized to be appro18 priated to carry out this section, and this section shall be 

19 carried out using amounts otherwise available for such 

20 purpose. 

Æ